Madagascar Finds Keen Takers for Tonic Touted as Virus Drug
(Bloomberg) -- Madagascar is building a factory to mass-produce a drink that's touted by authorities and some African leaders as a ‘cure' for Covid-19 even though it hasn't been clinically tested or approved by drug regulators.
Sold as Covid-Organics, the drink contains extracts of the artimisia annua plant, which is used to treat malaria. The factory will be operational within a month, according to President Andry Rajoelina. “Our researchers and scientists are doing the necessary to make our coronavirus remedy a drug that meets the standards,” he said on state TV.
The president of Tanzania, John Magufuli, has said he's sending a plane to Madagascar to fetch the tonic, and Rajoelina said on Twitter that Equatorial Guinea's vice minister for health had arrived in the country to procure an unknown quantity. Other countries that have shown interest are Guinea-Bissau and Comoros, Rajoelina said.
While Senegal has also put in a purchase order, a doctor who's instrumental in the country's coronavirus response, Moussa Seydi, cautioned against the tonic in a televised debate late Monday.
”As a doctor, I wouldn't use it before knowing the drug has been tried and tested in a laboratory,” Seydi said. “You need a study, with tests carried out on human beings.”
Medicinal plants such as artemisia annua should be “tested for efficacy and adverse side effects,” the World Health Organization said in a statement. “Africans deserve to use medicines tested to the same standards as people in the rest of the world.”
©2020 Bloomberg L.P.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.